Resisting resistance: Maximizing the durability of antiretroviral therapy

被引：27

作者：

Condra, JH ^{[1
]}

机构：

[1] Merck & Co Inc, Dept Antiviral Res, West Point, PA 19486 USA

来源：

ANNALS OF INTERNAL MEDICINE | 1998年 / 128卷 / 11期

关键词：

D O I：

10.7326/0003-4819-128-11-199806010-00017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：951 / 954

页数：4

共 20 条

[11]

GULICK RM, 1997, 37 INT C ANT AG CHEM, P1

[12] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].

Hammer, SM ;

Squires, KE ;

Hughes, MD ;

Grimes, JM ;

Demeter, LM ;

Currier, JS ;

Eron, JJ ;

Feinberg, JE ;

Balfour, HH ;

Dayton, LR ;

Chodakewitz, JA ;

Fischl, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733

[13]

HERTOGS K, 1998, 5 C RETR OPP INF 1 5, P153

[14] In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies [J].

Jacobsen, H ;

Hanggi, M ;

Ott, M ;

Duncan, IB ;

Owen, S ;

Andreoni, M ;

Vella, S ;

Mous, J .

JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (06) :1379-1387

[15]

LALEZARI J, 1996, INT C AIDS, V11, P29

[16] Ordered accumulation of mutations in HIV protease confers resistance to ritonavir [J].

Molla, A ;

Korneyeva, M ;

Gao, Q ;

Vasavanonda, S ;

Schipper, PJ ;

Mo, HM ;

Markowitz, M ;

Chernyavskiy, T ;

Niu, P ;

Lyons, N ;

Hsu, A ;

Granneman, GR ;

Ho, DD ;

Boucher, CAB ;

Leonard, JM ;

Norbeck, DW ;

Kempf, DJ .

NATURE MEDICINE, 1996, 2 (07) :760-766

[17] Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease [J].

Patick, AK ;

Markowitz, M ;

Appelt, K ;

Wu, B ;

Musick, L ;

Kalish, V ;

Kaldor, S ;

Reich, S ;

Ho, D ;

Webber, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) :292-297

[18]

Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008

[19] CROSS-RESISTANCE ANALYSIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS INDIVIDUALLY SELECTED FOR RESISTANCE TO 5 DIFFERENT PROTEASE INHIBITORS [J].

TISDALE, M ;

MYERS, RE ;

MASCHERA, B ;

PARRY, NR ;

OLIVER, NM ;

BLAIR, ED .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1704-1710

[20] Clinically effective HIV-1 protease inhibitors [J].

Vacca, JP ;

Condra, JH .

DRUG DISCOVERY TODAY, 1997, 2 (07) :261-272

← 1 2 →